Literature DB >> 15921396

CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity.

Régis Bataille, Nelly Robillard, Hervé Avet-Loiseau, Jean-Luc Harousseau, Philippe Moreau.   

Abstract

We investigated the expression of insulin-like growth factor-1 receptor (CD221) in normal, reactive and malignant plasma cells. We show that CD221 is aberrantly expressed on human myeloma cells, that higher levels of CD221 are observed in patients and human myeloma cell lines with the most aggressive 14q32 translocations, and that CD221 expression has a negative prognostic impact in patients with multiple myeloma.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15921396

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  24 in total

1.  A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines.

Authors:  Jérôme Moreaux; Bernard Klein; Régis Bataille; Géraldine Descamps; Sophie Maïga; Dirk Hose; Hartmut Goldschmidt; Anna Jauch; Thierry Rème; Michel Jourdan; Martine Amiot; Catherine Pellat-Deceunynck
Journal:  Haematologica       Date:  2010-12-20       Impact factor: 9.941

2.  Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.

Authors:  Deborah J Kuhn; Zuzana Berkova; Richard J Jones; Richard Woessner; Chad C Bjorklund; Wencai Ma; R Eric Davis; Pei Lin; Hua Wang; Timothy L Madden; Caimiao Wei; Veerabhadran Baladandayuthapani; Michael Wang; Sheeba K Thomas; Jatin J Shah; Donna M Weber; Robert Z Orlowski
Journal:  Blood       Date:  2012-08-29       Impact factor: 22.113

Review 3.  The development of potential antibody-based therapies for myeloma.

Authors:  Daniel W Sherbenou; Christopher R Behrens; Yang Su; Jeffrey L Wolf; Thomas G Martin; Bin Liu
Journal:  Blood Rev       Date:  2014-09-28       Impact factor: 8.250

4.  Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders.

Authors:  Jooeun Bae; Yu-Tzu Tai; Kenneth C Anderson; Nikhil C Munshi
Journal:  Br J Haematol       Date:  2011-09-09       Impact factor: 6.998

5.  Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activation.

Authors:  A C Sprynski; D Hose; A Kassambara; L Vincent; M Jourdan; J F Rossi; H Goldschmidt; B Klein
Journal:  Leukemia       Date:  2010-09-16       Impact factor: 11.528

6.  Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium.

Authors:  Brenda M Birmann; Marian L Neuhouser; Bernard Rosner; Demetrius Albanes; Julie E Buring; Graham G Giles; Qing Lan; I-Min Lee; Mark P Purdue; Nathaniel Rothman; Gianluca Severi; Jian-Min Yuan; Kenneth C Anderson; Michael Pollak; Nader Rifai; Patricia Hartge; Ola Landgren; Lawrence Lessin; Jarmo Virtamo; Robert B Wallace; JoAnn E Manson; Graham A Colditz
Journal:  Blood       Date:  2012-10-16       Impact factor: 22.113

7.  Syndecan-1 (CD138) Suppresses Apoptosis in Multiple Myeloma by Activating IGF1 Receptor: Prevention by SynstatinIGF1R Inhibits Tumor Growth.

Authors:  DeannaLee M Beauvais; Oisun Jung; Yang Yang; Ralph D Sanderson; Alan C Rapraeger
Journal:  Cancer Res       Date:  2016-06-30       Impact factor: 12.701

8.  The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor.

Authors:  Anne Catherine Sprynski; Dirk Hose; Laurent Caillot; Thierry Réme; John D Shaughnessy; Bart Barlogie; Anja Seckinger; Jérôme Moreaux; Michael Hundemer; Michel Jourdan; Tobias Meissner; Anna Jauch; Karène Mahtouk; Alboukadel Kassambara; Uta Bertsch; Jean François Rossi; Hartmut Goldschmidt; Bernard Klein
Journal:  Blood       Date:  2009-02-18       Impact factor: 22.113

9.  Experimental approaches in the treatment of multiple myeloma.

Authors:  Saad A Khan; Adam D Cohen
Journal:  Ther Adv Hematol       Date:  2011-08

10.  A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45.

Authors:  G Descamps; P Gomez-Bougie; C Venot; P Moreau; R Bataille; M Amiot
Journal:  Br J Cancer       Date:  2009-01-27       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.